Abstract
Purpose :
Practice patterns and treatment outcomes of Central Serous Chorioretinopathy (CSCR) in the United States are varied. To study the current treatment patterns and outcomes in CSCR, we examined a large database focusing on visual acuity (VA) and central subfield thickness (CST) changes following various treatments.
Methods :
Retrospective data collection and analysis of patients presenting with CSCR from January 2015 to September 2022 was conducted using the Vestrum Health Retina Database of aggregated de-identified electronic medical records from retina specialists in the US. Cases of CSCR were categorized by age, sex, and treatment. VA and CST changes were compared between groups using R-4.1.3.
Results :
Annual incidence of CSCR was 1.72% (61,755/3,598,672 patient eyes) from January 2015 to September 2022, with an average age of 53 ± 13.7 years (Figure 1A). 71.8% (44,333/61,755) of the patients were male. A large majority of patients (52,543, 85%) received no treatment within 1 year of diagnosis. Of the patients needing treatment, 21% received thermal laser therapy, 23% photodynamic therapy (PDT), and 49% anti-vascular endothelial growth factor (anti-VEGF) intraocular injection. The remaining 7% received a combination of treatments. Patients receiving no treatment had the best baseline and one-year VA. All treatments improved VA at 12 months and increased the percent of patients gaining letters in comparison to no treatment (Figure 1B-C).
Conclusions :
While the majority of patients did not require treatment, treated patients generally did well, with a large proportion demonstrating visual gain. Statistical analysis suggests a positive impact of treatment on VA outcomes. Patients receiving combination treatment were older and had the least visual gain of the treated cohorts. Patients within the no treatment group had both the highest VA at baseline and at one year, which supports the self-limited and self-resolving nature of CSCR in the majority of cases.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.